Tamiflu Population Differences Could Be Studied In U.K, HMO Databases
Executive Summary
Population differences with regard to serious adverse events in patients receiving Roche's antiviral Tamiflu could be explored using large databases, such as the U.K. General Practitioner Research Database and the UnitedHealthcare database, FDA's Pediatric Advisory Committee suggested on Nov. 18